BOSTON SCIENTIFIC CORPORATION Other Operating Activities, Cash Flow Statement
BOSTON SCIENTIFIC CORPORATION (BSX) reported Other Operating Activities, Cash Flow Statement of $63.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherOperatingActivitiesCashFlowStatement · last filed 2026-08-03
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for the quarter ending 2026-06-30 was $36.00M, a 54.43% decline year-over-year.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for the quarter ending 2026-03-31 was $27.00M.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for the quarter ending 2025-12-31 was $20.00M, a 100.00% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for the quarter ending 2025-09-30 was -$50.00M.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for fiscal 2025 was $42.00M, a 2000.00% increase from fiscal 2024.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for fiscal 2024 was $2.00M, a 95.74% decline from fiscal 2023.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for fiscal 2023 was $47.00M, a 62.40% decline from fiscal 2022.
- BOSTON SCIENTIFIC CORPORATION other operating activities, cash flow statement for fiscal 2022 was $125.00M, a 60.26% increase from fiscal 2021.
| Period end | Other Operating Activities, Cash Flow Statement 3 month | Other Operating Activities, Cash Flow Statement 6 month | Other Operating Activities, Cash Flow Statement 9 month | Other Operating Activities, Cash Flow Statement 9 month as first filed | Other Operating Activities, Cash Flow Statement 12 month | Other Operating Activities, Cash Flow Statement 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $36.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $63.00M 10-Q · filed 2026-08-03 | $83.00M derived: sum of 3 quarters · filed 2026-08-03 | $33.00M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $27.00M 10-Q · filed 2026-05-01 | $47.00M derived: sum of 2 quarters · filed 2026-05-01 | -$3.00M derived: sum of 3 quarters · filed 2026-05-01 | $76.00M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$30.00M derived: sum of 2 quarters · filed 2026-02-17 | $49.00M derived: sum of 3 quarters · filed 2026-08-03 | $42.00M 10-K · filed 2026-02-17 | ||
| 2025-09-30 | -$50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $29.00M derived: sum of 2 quarters · filed 2026-08-03 | $22.00M 10-Q · filed 2025-11-03 | $32.00M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $79.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $72.00M 10-Q · filed 2026-08-03 | $82.00M derived: sum of 3 quarters · filed 2026-08-03 | $66.00M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | -$7.00M 10-Q · filed 2026-05-01 | $3.00M derived: sum of 2 quarters · filed 2026-05-01 | -$13.00M derived: sum of 3 quarters · filed 2026-05-01 | -$1.00M derived: sum of 4 quarters · filed 2026-05-01 | ||
| 2024-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$6.00M derived: sum of 2 quarters · filed 2026-02-17 | $6.00M derived: sum of 3 quarters · filed 2026-02-17 | $2.00M 10-K · filed 2026-02-17 | $74.00M 10-K · filed 2025-02-18 | |
| 2024-09-30 | -$16.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$4.00M derived: sum of 2 quarters · filed 2025-11-03 | -$8.00M 10-Q · filed 2025-11-03 | $22.00M 10-Q · filed 2024-11-01 | $6.00M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $8.00M 10-Q · filed 2025-08-01 | $22.00M derived: sum of 3 quarters · filed 2026-02-17 | $32.00M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-03-31 | -$4.00M 10-Q · filed 2025-05-01 | $10.00M derived: sum of 2 quarters · filed 2026-02-17 | $20.00M derived: sum of 3 quarters · filed 2026-02-17 | $45.00M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2023-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $24.00M derived: sum of 2 quarters · filed 2026-02-17 | $49.00M derived: sum of 3 quarters · filed 2026-02-17 | $47.00M 10-K · filed 2026-02-17 | $73.00M 10-K · filed 2024-02-20 | |
| 2023-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $35.00M derived: sum of 2 quarters · filed 2024-11-01 | $33.00M 10-Q · filed 2024-11-01 | $66.00M derived: sum of 4 quarters · filed 2025-02-18 | ||
| 2023-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $23.00M 10-Q · filed 2024-08-01 | $56.00M derived: sum of 3 quarters · filed 2025-02-18 | |||
| 2023-03-31 | -$2.00M 10-Q · filed 2024-05-01 | $31.00M derived: sum of 2 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $125.00M 10-K · filed 2025-02-18 | ||||
| 2022-09-30 | $92.00M 10-Q · filed 2023-11-01 | |||||
| 2021-12-31 | $78.00M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |